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DrOBJECTIVES The aim of the CATCH (CArdiac cT in the treatment of acute CHest pain) trial was to investigate the long-
term clinical impact of a coronary computed tomographic angiography (CTA)-guided treatment strategy in patients with
recent acute-onset chest pain compared to standard care.
BACKGROUND The prognostic implications of a coronary CTA-guided treatment strategy have not been compared in a
randomized fashion to standard care in patients referred for acute-onset chest pain.
METHODS Patients with acute chest pain but normal electrocardiograms and troponin values were randomized to
treatment guided by either coronary CTA or standard care (bicycle exercise electrocardiogram or myocardial perfusion
imaging). In the coronary CTA-guided group, a functional test was included in cases of nondiagnostic coronary CTA
images or coronary stenoses of borderline severity. The primary endpoint was a composite of cardiac death, myocardial
infarction (MI), hospitalization for unstable angina pectoris (UAP), late symptom-driven revascularizations, and read-
mission for chest pain.
RESULTS We randomized 299 patients to coronary CTA-guided strategy and 301 to standard care. After inclusion,
24 patients withdrew their consent. The median (interquartile range) follow-up duration was 18.7 (range 16.8 to 20.1)
months. In the coronary CTA-guided group, 30 patients (11%) had a primary endpoint versus 47 patients (16%) in the
standard care group (p ¼ 0.04; hazard ratio [HR]: 0.62 [95% conﬁdence interval: 0.40 to 0.98]). A major adverse
cardiac event (cardiac death, MI, hospitalization for UAP, and late symptom-driven revascularization) was observed in 5
patients (2 MIs, 3 UAPs) in the coronary CTA-guided group versus 14 patients (1 cardiac death, 7 MIs, 5 UAPs, 1 late
symptom-driven revascularization) in the standard care group (p ¼ 0.04; HR: 0.36 [95% CI: 0.16 to 0.95]). Differences in
cardiac death and MI (8 vs. 2) were insigniﬁcant (p ¼ 0.06).
CONCLUSIONS A coronary CTA-guided treatment strategy appears to improve clinical outcome in patients with recent
acute-onset chest pain and normal electrocardiograms and troponin values compared to standard care with a functional
test. (Cardiac-CT in the Treatment of Acute Chest Pain [CATCH]; NCT01534000) (J Am Coll Cardiol Img 2015;8:1404–13)
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
CAD = coronary artery disease
CTA = computed tomographic
angiography
ECG = electrocardiogram
ICA = invasive coronary
angiography
MACE = major adverse
cardiovascular events
MI = myocardial infarction
SPECT = single-photon
emission computed
tomography
UAP = unstable angina pectoris
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1405P atients presenting with acute chest pain maysuffer from vasospastic or structural coronarypathology as the main cause of their symp-
toms (1). However, a large proportion of patients
have noncardiac causes of chest pain, which makes
it difﬁcult to identify those with coronary artery
disease (CAD) and, hence, the need for revasculari-
zation or intensive medical treatment (2–4). Patients
with acute chest pain appear to have increased risk
of future cardiovascular events even if electrocar-
diograms (ECG) and cardiac biomarkers are normal
(5,6). For several decades, functional tests,
including exercise ECG or single-photon emission
computed tomography (SPECT) have been corner-
stones of the initial diagnostic strategy used to
select patients for invasive coronary angiography
(ICA). However, because ICA has a relatively low
diagnostic yield of 30% to 40%, an improved evalu-
ation strategy seems necessary (7). Coronary
computed tomographic angiography (CTA) providesSEE PAGE 1414detailed anatomical information about coronary pa-
thology with high diagnostic accuracy to exclude
CAD (8,9). In current American and European guide-
lines concerning diagnosis and management of pa-
tients with stable CAD or low-risk unstable angina,
exercise ECG and SPECT are established as ﬁrst
line noninvasive tests in patients with a broad range
of pretest probabilities, whereas the role of coronary
CTA is considered mainly a second line approach
(10,11). Randomized trials and a meta-analysis have
demonstrated that the addition of coronary CTA in
the early triage of unselected patients with chest
pain is safe and reduces costs and lengths of stay
in the emergency department (12–16). However, the
impact of coronary CTA performed after discharge
on the clinical outcome has not been investigated
in patients initially referred for acute coronary syn-
drome (ACS).
The intent of the CATCH (CArdiac cT in the treat-
ment of acute CHest pain) trial was to evaluate
whether a post-discharge coronary CTA-guided diag-
nostic strategy improved long-term clinical outcome
in patients referred for ACS, who had normal ECGs
and troponin values.CORE320 trial, which was supported in part by Toshiba Medical Corporati
Medical Systems, and the advisory board for Vital Images, Inc.; and has receiv
McKinney, Møllers Fond, The John and Birthe Meyer Foundation, Research
hagen, The Danish Heart Foundation, The Lundbeck Foundation, and The Da
by The Danish Council for Strategic Research. All other authors have repor
contents of this paper to disclose.
Manuscript received June 16, 2015; revised manuscript received July 26, 201METHODS
DESIGN AND STUDY POPULATION. The
CATCH trial was a randomized, controlled,
parallel group trial designed to investigate the
clinical value of a coronary CTA-guided diag-
nostic strategy compared to standard care
with a functional test (NCT01534000). Base-
line results from the CATCH trial concerning
the effect of a coronary CTA-guided strategy
on the referral rate for ICA, the positive
predictive value for the identiﬁcation of sig-
niﬁcant CAD, and subsequent coronary
revascularization have previously been pub-
lished (17). Patients referred for ACS, who
turned out to have normal or nondiagnostic
ECGs and 2 normal measures of troponin
concentrations and who could be discharged after
approximately 24 h of in-hospital clinical observation
without reoccurrence of chest pain, were considered
for enrollment in the trial in case the treating cardi-
ologist found indication for further outpatient evalu-
ation of the patient. Using these criteria, we aimed to
include a study population with a low to intermediate
pre-test probability of CAD (18). Exclusion criteria
were age of <18 years, women of childbearing poten-
tial not using approved contraception, patients with
geographical residence or mental or physical condi-
tions that would impair follow-up, plasma creatinine
concentrations >130 mg/l, known allergy to iodinated
contrast agents, abnormal chest radiography, and
previous coronary artery bypass graft surgery. Pa-
tients were consecutively included in the study within
7 days after hospital admission, and noninvasive tests
were performed within 2 weeks from randomization.
The study protocol was approved by the local ethics
committee and complied with the Declaration of
Helsinki.
RANDOMIZATION AND BLINDING. After informed
consent was obtained, patients were randomized in a
1:1 ratio to either coronary CTA-guided investigation
or standard care based on functional testing. Details
of the randomization process were previously pub-
lished (17). To secure blinding of patients with regard
to group allocation, all treatments were planned soon; is a member of the speakers bureau of Toshiba
ed research grants from APMøller og hustru Chastine
Council of Rigshopitalet, The University of Copen-
nish Agency for Science, Technology and Innovation
ted that they have no relationships relevant to the
5, accepted July 30, 2015.
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1406that patients would undergo both post-discharge
coronary CTA evaluation and functional testing. In
the coronary CTA-guided group, the result of the
coronary CTA was sent to the referring physician,
who determined the subsequent strategy according
to the protocol detailed below. In the standard care
group, the coronary CTA was not reconstructed or
analyzed, and results remained blinded to the pa-
tient and to the referring physician throughout the
study.
INDEX DIAGNOSTIC TESTING. Coronary CTA was
performed at Rigshospitalet, Copenhagen, using a 320
model multidetector CT scanner (Aquilion One,
Toshiba, Irvine, California). In the absence of con-
traindications, an oral beta-blocker (50 to 150 mg of
metoprolol) was given in advance whenever the heart
rate was >60 beats/min. The coronary CTA images
were interpreted independently by 2 experienced
coronary CTA readers (J.D.H. and K.F.K.) in accor-
dance with guidelines published by the Society of
Cardiovascular Computed Tomography (19). In the
case of disagreement, a ﬁnal conclusion was made in
consensus. Patients with a coronary diameter steno-
sis >50% in the left main artery or $70% in one of the
major coronary artery branches with a lumen diam-
eter >2 mm were referred for ICA. In patients with a
borderline coronary artery diameter stenosis between
50% and 70% or a nondiagnostic coronary CTA due to
motion or other artifacts, excessive calciﬁcations, or
nonevaluable coronary stents, the coronary CTA
report sent to the referring physician included a
recommendation to add functional testing to the
clinical decision. In these cases, results of the stress
test were made available for the treating physician.
A coronary diameter stenosis <50% was considered
nonsigniﬁcant.
The exercise ECG test was performed in accor-
dance with European guidelines (20). Patients with
insufﬁcient physical capacity and patients with
nondiagnostic exercise ECG tests were scheduled
for SPECT conducted according to established
guidelines (21). In the standard care group, patients
with a positive exercise ECG test result or a positive
or nondiagnostic SPECT result were referred for
ICA.
Decision to perform coronary intervention was left
to the interventional cardiologist, who was not part of
the study team. Fractional ﬂow reserve measurement
was performed in patients with borderline coronary
stenoses on ICA.
OUTCOME MEASURES. The primary endpoint was
the composite of cardiac death, myocardial infarction
(MI), hospitalization for unstable angina pectoris(UAP), late symptom-driven revascularization, and
readmission for chest pain. Secondary endpoints
were major adverse cardiac events (MACE), deﬁned as
the composite of all components of the primary
endpoint excluding readmission for chest pain, and
the individual components of the primary endpoint.
The ﬁrst occurring event for each patient was used in
both of the outcome analyses. Speciﬁcally, patients
readmitted for chest pain who later also experienced
MACE were classiﬁed as “readmission for chest pain”
in the primary endpoint outcome analysis, whereas
the subsequent major event was applied in the
MACE outcome analysis. Information of post-index
diagnostic tests in the follow-up period, including
exercise ECG, SPECT, coronary CTA, and ICA was
obtained, and information of medical treatment was
recorded at baseline and after the index diagnostic
evaluation. Medical treatment and decision to refer
for new diagnostic testing after index evaluation was
left to the treating physicians. Quality of life was
assessed at the time of follow-up, using the Interna-
tional Quality of Life Assessment SF-36 questionnaire
(22). In the coronary CTA-guided group, extra-cardiac
ﬁndings meriting further investigation and treatment
were recorded.
STUDY ENDPOINTS. Follow-up initiated after at least
1 year with registration of clinical endpoints was
conducted by 2 dedicated project nurses. Patients
were contacted by letter with a suggested time for a
phone interview, and electronic records covering all
hospital admissions in the eastern part of Denmark
were reviewed for conﬁrmation of exact dates and
diagnoses. Failure to reach the patient by phone was
followed by a second and, thereafter, a third letter
with a new suggested date for the interview. If con-
tact was not achieved following this protocol, hospi-
tal records were reviewed at the timepoint for the
third suggested interview with recording of clinical
endpoints. After completion of data acquisition,
blinded adjudication of clinical endpoints was per-
formed independently by 2 experienced cardiologists.
A detailed description of the adjudication process
including deﬁnitions of study endpoints is available
in the Online Appendix.
STATISTICAL ANALYSIS. The sample size calculation
is available in the Online Appendix. All analyses were
performed according to the intention-to-treat princi-
ple, except that patients who withdrew their consent
were excluded. Continuous data are mean  SD or
median (interquartile range) and were compared
using the Student t test for unpaired data, Fisher
exact test, or the Kruskal-Wallis test as appropriate.
A 2-sided p value <0.05 was considered statistically
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1407signiﬁcant. The primary endpoint and its individual
components were compared with log-rank testing,
and for the primary endpoint and MACE, the hazard
ratios (HRs) were obtained from Cox proportional
hazard models. Patients who died of noncardiac
causes were censored at the time of death, unless a
cardiac event had already been recorded. SAS version
9.1.3 software (SAS, Cary, North Carolina) was used
for statistical analyses.
RESULTS
From January 2010 to January 2013, 847 patients were
screened for eligibility in the CATCH trial to include
600 patients. Of 299 patients randomized to coronary
CTA-guided strategy and 301 patients to standard
care strategy, 14 and 10 patients (4% in total) subse-
quently withdrew their consent before any diagnostic
test was performed. Figure 1 shows the patient ﬂow
chart. Demographics were comparable between theFIGURE 1 Study Flow Diagram
847 Assesse
14 Withdrew Consent
299 Assigned to the Coronary CTA-guided Group
285 Included in the Analysis
Rand
(n 
Follow-up Completed in 285 Patients
257 assessed by phone-interview and
review of electronic hospital records
28 assessed by review of electronic
hospital records
Flow diagram shows patient eligibility, randomization, and follow-up. C2 groups, except for hypertension, which was more
common in the coronary CTA-guided group (Table 1).
In the coronary CTA-guided group, the treatment
strategy during index evaluation was based on coro-
nary CTA in 233 patients (82%), a combination of
coronary CTA and functional test in 39 patients
(25 patients with borderline coronary CTA stenosis
and 14 patients with nondiagnostic coronary CTA;
14% in total), and a functional test alone in 13 patients
(5%). Of patients with borderline coronary CTA
stenoses or nondiagnostic images, evaluation and
treatment strategy were based on exercise ECG in 24
patients (62%), of whom 12 patients were referred for
ICA, but none was revascularized, and on SPECT in 15
patients (38%), of whom 5 patients were referred for
ICA due to a reversible perfusion defect (1 patient was
revascularized). In the standard care group, clinical
treatment strategy was based on an exercise ECG test
in 221 patients (76%), SPECT in 63 patients (22%), and
clinical assessment by a cardiologist without anyd for Eligibility
10 Withdrew Consent
301 Assigned to the Standard Care Group
291 Included in the Analysis
omized
= 600)
247 Excluded
 121 met an exclusion criteria
 99 declined to participate
 27 logistics
Follow-up Completed in 291 Patients
261 assessed by phone-interview and
review of electronic hospital records
30 assessed by review of electronic
hospital records
TA ¼ computed tomographic angiography.
TABLE 1 Baseline Characteristics of Patients Evaluated by Coronary CTA-Guided Strategy
Versus Those by Standard Care
Coronary
CTA-Guided Strategy
(n ¼ 285)
Standard Care
Strategy
(n ¼ 291) p Value
Age, yrs 56  12 55  12 0.14
Women 124 (44) 123 (42) 0.76
BMI, kg/m2* 28 (24–31) 28 (24–31) 0.60
Hypertension 135 (47) 106 (36) 0.009
Hyperlipidemia 117 (41) 101 (35) 0.12
Diabetes 35 (12) 29 (10) 0.38
Family history of CAD 69 (24) 76 (26) 0.63
Active users of tobacco or ex-smoker 172 (60) 195 (67) 0.10
History of CAD 44 (15) 36 (12) 0.29
Previous PCI 30 (11) 26 (9) 0.31
Symptoms
Typical angina 35 (12) 34 (12) 0.83
Atypical angina 110 (39) 116 (40) 0.76
Nonanginal chest pain 140 (49) 141 (48) 0.88
Pre-test risk† 36  27 34  26 0.37
Pre-test risk group†
Low (0%–15%) 59 (21) 60 (21) 1.00
Low to intermediate (15%–50%) 96 (34) 120 (41) 0.07
Intermediate (15%–85%) 161 (56) 173 (59) 0.50
High (>85%) 21 (7) 22 (8) 1.00
TIMI risk score
0 139 (49) 158 (54) 0.21
1 77 (27) 71 (24) 0.50
2 37 (13) 32 (11) 0.52
$3 32 (11) 30 (10) 0.79
Median coronary calcium score* 5 (0–154)
Medication after index evaluation
Aspirin 134 (47) 106 (36) 0.01
Statin 125 (44) 110 (38) 0.15
Beta-blocker 67 (24) 54 (19) 0.15
Calcium-blockers 52 (18) 33 (11) 0.03
Nitrates 49 (17) 33 (11) 0.06
Diuretics 61 (21) 41 (14) 0.02
ACE-inhibitors/AT2-antagonist 76 (27) 69 (24) 0.44
Platelet inhibitors 40 (14) 18 (6) 0.002
Values are mean  SD, n (%), or median (IQR). *Interquartile range (25th-75th). †Pre-test risk of having sig-
niﬁcant coronary artery disease, according to criteria of Diamond and Forrester (18) based on age, sex, and type
of chest pain. Patients with a history of CAD were excluded.
ACE ¼ angiotensin-converting-enzyme; AT2 ¼ angiotensin 2; BMI ¼ body mass index (weight [kg]/
height2[m2]); CAD ¼ coronary artery disease; CTA ¼ computed tomographic angiography; PCI ¼ percutaneous
coronary intervention; TIMI ¼ thrombolysis in myocardial infarction.
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1408functional test in 7 patients (2%). In the standard care
group, 22 patients with known CAD were evaluated
by exercise ECG and 12 by SPECT and by clinical
evaluation alone in 2 patients. During index evalu-
ation, 85 patients were referred for ICA, of whom
9 patients underwent fractional ﬂow reserve due to
an intermediate diameter stenosis (7 in the coronary
CTA-guided group and 2 in the standard care
group). In the coronary CTA-guided group, 14
of 49 patients (29%) had normal ICA versus 23 of
36 patients (64%) in the standard care group(p ¼ 0.002). In the coronary CTA-guided group, no
extra-cardiac ﬁndings by full-view CT examination
required treatment.
Follow-up with regard to clinical events was
completed in all patients. Combined phone in-
terviews and reviews of electronic hospital records
were possible for 257 patients (90%) in the coronary
CTA-guided group and 261 patients (90%) in the
standard care group (p ¼ 0.89). For the remaining
patients, event registration was obtained by review
of electronic hospital records alone. No events
recorded in patients completing the planned phone
interview were missed by the corresponding elec-
tronic hospital records. The median follow-up
duration was 18.7 months (interquartile range
[IQR]: 16.8 to 20.1 months), with no differences
between groups.
POST-INDEX REPEATED ELECTIVE DIAGNOSTIC
TESTING AND QUALITY OF LIFE. The frequencies of
elective diagnostic tests after index evaluation were
similar in the 2 groups, and no differences in any life
quality scores were observed between the groups at
follow-up (Online Tables 1 and 2).
MEDICAL TREATMENT. After index diagnostic eval-
uation, more patients were treated with aspirin
and other platelet inhibitors in the coronary
CTA-guided group (Table 1). In addition, patients
in the coronary CTA-guided group were more
frequently treated with calcium-blockers and
diuretics, but a similar pattern was observed before
randomization.
CLINICAL OUTCOME. Frequencies and types of
events are presented in Table 2, and occurrence of
events over time is presented in Figure 2. In the cor-
onary CTA-guided group 2 patients died from
noncardiac causes (liver cirrhosis and pulmonary
cancer). However, fewer patients in that group suf-
fered a primary endpoint (cardiac death, MI, UAP, late
symptom-driven revascularization and readmission
for chest pain) than those in the standard care group
(HR: 0.62 [95% conﬁdence interval (CI): 0.40 to
0.98]). In a cox proportional hazard model including
baseline hypertension and hyperlipidemia, differ-
ences between strategies remained signiﬁcant (HR:
0.57 [95% CI: 0.36 to 0.91]; p ¼ 0.02). A signiﬁcant risk
reduction was also found for the composite of MACE
(the composite of all components of the primary
endpoint, excluding readmission for chest pain)
(HR: 0.36 [95% CI: 0.16 to 0.95]) (Figure 2). Differ-
ences in cardiac death and MIs (8 vs. 2, respectively)
were insigniﬁcant (p ¼ 0.06). Of the 9 patients who
had MIs, 2 had ST-segment elevation myocardial
infarction (both in the standard care group) and
TABLE 2 Clinical Outcome of Patients Evaluated by a Coronary CTA-Guided Strategy
Versus Standard Care
Coronary
CTA-Guided Strategy
(n ¼ 285)
Standard Care
Strategy
(n ¼ 291) p Value
No. at primary endpoint 30 (11) 47 (16) 0.04
First occurring event
Cardiac death 0 (0) 1 (0) 1.00
Myocardial infarction 1 (0) 7 (2) 0.07
Unstable angina pectoris 3 (1) 2 (1) 0.7
Late symptom-driven revascularization 0 (0) 1 (0) 1.00
Readmission for chest pain 26 (10) 36 (12) 0.23
No. of MACE 5 (2) 14 (5) 0.04
First MACE
Cardiac death 0 (0) 1 (0) 1.00
Myocardial infarction* 2 (1) 7 (2) 0.18
Unstable angina pectoris* 3 (1) 5 (2) 0.72
Late symptom-driven revascularization 0 (0) 1 (0) 1.00
Values are n (%). *For the distribution of the different components of the primary endpoint and the composite of
major adverse cardiac events (MACE), only the ﬁrst occurring type of event is shown. MACE was deﬁned as the
composite of all components of the primary endpoint, excluding readmission with chest pain. Comparisons are
made by log-rank testing for primary and secondary endpoints.
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14097 had non-ST-segment elevation myocardial infarc-
tion. All patients presented with chest pain and
had elevated troponin concentrations. Two patients
had normal ECGs, and all but 2 patients subse-
quently underwent coronary revascularization. Of
patients readmitted for chest pain, 7 patients (11%)
had renewed out-patient diagnostic testing (3 exer-
cise ECG, 3 SPECT, and 1 ICA).
The relationship of index diagnostic evaluation
and intervention with cardiovascular events during
follow-up is illustrated in Table 3. During index
evaluation, revascularization was more frequently
performed as a consequence of coronary CTA-guided
assessment, compared to standard care with func-
tional testing. Subgroup analyses of patients grouped
according to pre-test probability and presence or
absence of known CAD are presented in Table 4.
DISCUSSION
The CATCH trial evaluated in a randomized fashion
the long-term clinical value of a coronary CTA-guided
treatment strategy in patients referred for acute
chest pain, who turned out to have normal ECGs and
plasma troponin levels. We found that a coronary
CTA-guided treatment strategy reduced the risk of
suffering a cardiovascular event compared to stan-
dard evaluation with a functional test. This differenceFIGURE 2 Long-Term Clinical Outcome
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Kaplan-Meier curves show event-free survival of the primary compositeremained signiﬁcant when excluding the soft end-
point of readmission for chest pain.
A coronary CTA-guided strategy identiﬁed more
patients with signiﬁcant CAD and resulted in a higher
frequency of index revascularizations, compared to
standard care. A possible explanation for an improvedded
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endpoint (left) and major adverse cardiac events (MACE) (right).
TABLE 3 Index Diagnostic Evaluation, Coronary Intervention, and Cardiovascular Events During Follow-Up
Coronary CTA-Guided Care Strategy Standard Care Strategy (Exercise ECG/SPECT)
p ValueTotal
Signiﬁcant
Stenosis
No Signiﬁcant
Stenosis
Borderline
Stenosis Nondiagnostic
No Test
or Stress
Test Only Total Ischemia
No
Ischemia Nondiagnostic
No
Test
Index evaluation/treatment
Noninvasive test result 285 31 202 25 14 13 291 29 240 15 7
Referred for ICA 49 31 0 9 7 2 36 28 3 4 1 0.13
Revascularized 29 26 0 1 0 2 12 10 0 2 0 0.006
PCI 25 23 0 1 0 1 8 6 0 2 0 0.002
CABG 4 3 0 0 0 1 4 4 0 0 0 1.00
Follow-up
Primary endpoint 30 6* 14† 7 3 0 47 10* 29† 5 3 0.04
Values are proportions of patients, and p values are comparisons between total number of patients who underwent coronary CTA-guided care and those who underwent standard care. *p ¼ 0.45 for
comparison between the proportions of patients with a primary endpoint events and those with a positive index noninvasive test. †p ¼ 0.03 for comparison between the proportions of patients with a primary
endpoint and those with a normal index noninvasive test result. In the standard care group, 192 patients had normal exercise ECG results, and 48 had normal SPECT results.
CABG ¼ coronary artery bypass grafting; CTA ¼ computed tomographic angiography; ECG ¼ electrocardiogram; ICA ¼ invasive coronary angiography; PCI ¼ percutaneous coronary intervention; SPECT ¼
single-photon emission computed tomography.
TABLE 4 Subgroup A
History of CAD
Primary endpoint
MACE
No History of CAD
Primary endpoint
MACE
Low pre-test probabilit
Primary endpoint
MACE
Intermediate pre-test p
Primary endpoint
MACE
High pre-test probabili
Primary endpoint
MACE
Values are n (%). *Patients
probabilities.
CAD ¼ coronary artery
MACE ¼ major adverse car
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1410outcome associated with a coronary CTA-guided
strategy therefore seems to be more well-timed and
appropriate coronary revascularization of this group.
Most events were reported in patients with a normal
index diagnostic test and more frequently after
standard care testing which indicate that much of the
difference found between groups can be explained by
false negative stress tests. This is supported by the
steep decline of the Kaplan-Meier curve in the stan-
dard care group within the ﬁrst month.nalyses With Regard to Primary Endpoint and MACE
Coronary
CTA-Guided
Strategy
(n ¼ 285)
Standard Care
Strategy
(n ¼ 291) p Value
Hazard Ratio
(95% CI)
44 (15) 36 (12) 0.29
12 (27) 12 (33) 0.49 0.76 (0.34–1.69)
4 (9) 5 (14) 0.49 0.63 (0.17–2.34)
241 (85) 255 (88) 0.34
18 (7) 38 (15) 0.02 0.53 (0.31–0.92)
1 (<1) 9 (4) 0.01 0.12 (0.06–0.73)
y* 59 (21) 60 (21) 1.00
2 (3) 5 (8) 0.25 0.40 (0.10–1.85)
0 (0) 0 (0) 1.00
robability* 161 (56) 173 (59) 0.50
14 (9) 24 (14) 0.13 0.61 (0.32–1.16)
1 (1) 7 (4) 0.04 0.15 (0.06–0.95)
ty* 21 (7) 22 (8) 1.00
2 (10) 6 (27) 0.12 0.30 (0.08–1.34)
0 (0) 2 (9) 0.14 0.00 (0.01–2.02)
with a history of CAD were excluded from subgroup analysis of differentiated pre-test
disease; CI ¼ conﬁdence interval; CTA ¼ computed tomographic angiography;
diac events.A change of medical regimen is another potential
contributing factor to the beneﬁcial effect of coronary
CTA on clinical patient outcome. After index evalua-
tion, more patients in the coronary CTA-guided group
were treated with aspirin and/or other platelet in-
hibitors, which potentially might have prevented
post-index events in some patients.
Previous randomized trials have focused on the
application of coronary CTA examination in the
emergency department to verify or repudiate ACS.
Hoffmann et al. (14) found that inclusion of coronary
CTA in the early triage of patients reduced the length
of stay in the hospital with no increase in MACE after
28 days and no increase in cost, even though down-
stream testing was increased. It has also been
demonstrated that a normal coronary CTA performed
in the emergency department allows patients to be
safely discharged with a low 30-day event rate, and 2
studies comparing coronary CTA with SPECT found
that coronary CTA reduced the time to make a correct
diagnosis and lowered overall cost (12,15,16). None of
these randomized trials investigated the mid- or long-
term prognostic value of coronary CTA. Two recently
published trials investigated the potential role of
coronary CTA compared to that of standard care in
patients with stable angina pectoris. SCOT-HEART
(Scottish COmputed Tomography of the HEART
Trial) evaluated the incremental value of coronary
CTA on top of standard care and found that additional
coronary CTA clariﬁed the diagnosis and enabled tar-
geting of interventions. Further, at 1.7 years coronary
CTA was associated with a 38% reduction in fatal and
nonfatal MI (26 vs. 42; HR: 0.62; 95% CI: 0.38 to 1.01;
p ¼ 0.053), which is consistent with ﬁndings in the
CATCH trial (23). In the PROMISE trial examination of
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testing (SPECT in 67%) did not result in any difference
of the primary composite endpoint (24). The risk of
death or nonfatal MI was, however, reduced in the
coronary CTA-group at 1 year. In addition coronary
CTA resulted in more revascularizations and less
redundant ICAs, which was conﬁrmed in our trial
where 29% had a normal ICA after coronary CTA,
compared to 64% after standard care. Concerning a
slightly different patient population the CATCH trial
therefore conﬁrms these ﬁndings and adds incre-
mental knowledge of the potential clinical beneﬁt of
coronary CTA.
CLINICAL IMPLICATIONS. According to the most
recent guidelines provided by the American College
of Cardiology Foundation/American Heart Associa-
tion (ACCF/AHA) Task Force and the European So-
ciety of Cardiology (ESC), patients with low-risk UAP
can be managed safely in an outpatient setting
(10,11). Most patients arriving in U.S. emergency
department have diagnostic testing performed
before discharge from the hospital, which is partly
related to concerns about losing the patients to
follow-up, which was supported by Poon et al. (25),
who found that only 21% of their patients received
an out-patient stress test within the follow-up
period. In Scandinavian countries, it is a common
strategy to perform diagnostic evaluation in an out-
patient setting to reduce the costs of acute imaging.
Patient compliance for this strategy is usually high,
as in our study, where 98% of patients in the stan-
dard care group underwent out-patient testing. A
primary event occurred before outpatient testing in
3 patients (0.5%), suggesting that this strategy was
acceptable with regard to safety. In the ACCF/AHA
guidelines, diagnostic evaluation by exercise ECG
and SPECT has Class 1 recommendation in patients
with intermediate pre-test probability (PTP) and in-
termediate to high PTP, respectively. In contrast
coronary CTA has only Class 2a recommenda-
tion. This is also consistent with the recently pub-
lished ACCF/AHA multimodality appropriate use
criteria for the detection and risk assessment of
stable CAD in which exercise ECG is appropriate in
patients with the ability to exercise and low or in-
termediate risk, whereas coronary CTA is rated
appropriate only in intermediate risk patients with
uninterpretable ECG or inability to exercise (26). In
the ESC guidelines concerning patients with stable
CAD, coronary CTA examination is recommended
in patients with a 15% to 50% PTP of CAD, whereas
exercise ECG was indicated in patients with a
PTP between 15% and 65% and SPECT for theintermediate risk group (PTP of 15% to 85%). In the
CATCH trial, most patients had a PTP within the low
to intermediate range, and we ﬁnd it important to
underline that in the subgroup of patients with a
PTP in the intermediate range (15% to 85%), we
found a signiﬁcant reduction in MACE with a coro-
nary CTA-guided strategy compared to a strategy
of standard functional testing. Our ﬁndings cont-
ribute further to the understanding of how a
broader implementation of a coronary CTA-guided
strategy in clinical practice could improve patient
management.
STUDY LIMITATIONS. The observed clinical event
rate in the standard care group was lower than
anticipated. Although, it was possible to detect a
signiﬁcant difference in primary outcome, our ﬁnd-
ings should be conﬁrmed in large-scale randomized
trials and meta-analyses. Patients and clinical staff
were blinded for group allocation until the index tests
were performed, but it was not possible to blind the
treating physicians during the follow-up period.
Medical treatment and decision to refer patients for
post-index noninvasive and/or invasive tests was left
to the referring physician and therefore could not be
controlled by the investigators. In the coronary CTA-
guided group, we used a pragmatic approach in
which a functional stress test was included as a
diagnostic tool in cases of nondiagnostic coronary
CTA images or in cases of borderline coronary artery
stenosis. This design excluded the possibility to
conclude how coronary CTA alone would inﬂuence
clinical outcome, and moreover it did not allow direct
methodological head to head comparisons between
coronary CTA and SPECT.
CONCLUSIONS
This randomized controlled trial concerning patients
hospitalized under the suspicion of ACS, who turned
out to have normal ECG and plasma troponin values,
suggests that a coronary CTA-guided strategy im-
proves long-term clinical outcome, compared to
standard care with functional tests.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Among
patients hospitalized for acute chest pain, who have
normal concentrations of plasma troponins and series of
electrocardiograms without signs of ischemia (low-risk
unstable angina), an out-patient coronary CTA-guided
diagnostic evaluation strategy appears to improve the
long-term clinical outcome, compared to standard eval-
uation with a functional test.
TRANSLATIONAL OUTLOOK: Previous randomized
trials on the clinical implementation of coronary CTA have
focused on logistical, safety and economic aspects of
patient management in the emergency department. The
CATCH trial monitored long-term clinical outcome and
therefore adds incremental evidence of a beneﬁcial clin-
ical value for patients with chest pain undergoing ﬁrst line
diagnostic evaluation with coronary CTA. However,
because the patient population studied in the CATCH trial
was evaluated in a post-discharge outpatient setting, the
long-term clinical value of early triage with coronary CTA
in the ED should be investigated in other randomized
studies.
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